Cargando…
Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
Introduction: Current gene therapy involves replacement of defective gene by delivery of healthy genetic material to precede normal function. Virus-mediated gene delivery is the most successful and efficient method for gene therapy, but it has been challenged due to serious safety concerns. Converse...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696419/ https://www.ncbi.nlm.nih.gov/pubmed/26125492 http://dx.doi.org/10.1517/14712598.2015.1057563 |
_version_ | 1782407792992190464 |
---|---|
author | Youn, Hyewon Chung, June-Key |
author_facet | Youn, Hyewon Chung, June-Key |
author_sort | Youn, Hyewon |
collection | PubMed |
description | Introduction: Current gene therapy involves replacement of defective gene by delivery of healthy genetic material to precede normal function. Virus-mediated gene delivery is the most successful and efficient method for gene therapy, but it has been challenged due to serious safety concerns. Conversely, gene delivery using plasmid DNA (pDNA) is considered safer, but its transfection efficiency is much lower than virus-mediated gene transfer. Recently, mRNA has been suggested as an alternative option to avoid undesired insertion of delivered DNA sequences with higher transfection efficiency and stability. Area covered: In this review, we summarize the currently available strategies of mRNA modification to increase the therapeutic efficacy; we also highlight the recent improvements of mRNA delivery for in vivo applications of gene therapy. Expert opinion: The use of mRNA-based gene transfer could indeed be a promising new strategy for gene therapy. Notable advantages include no risk of integration into the genomic DNA, adjustable gene expression and easier modulation of the immune system. By reducing or utilizing the immunogenic properties, mRNA offers a promising tool for gene/or transcript replacement. |
format | Online Article Text |
id | pubmed-4696419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Informa Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-46964192016-01-12 Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy Youn, Hyewon Chung, June-Key Expert Opin Biol Ther Review Introduction: Current gene therapy involves replacement of defective gene by delivery of healthy genetic material to precede normal function. Virus-mediated gene delivery is the most successful and efficient method for gene therapy, but it has been challenged due to serious safety concerns. Conversely, gene delivery using plasmid DNA (pDNA) is considered safer, but its transfection efficiency is much lower than virus-mediated gene transfer. Recently, mRNA has been suggested as an alternative option to avoid undesired insertion of delivered DNA sequences with higher transfection efficiency and stability. Area covered: In this review, we summarize the currently available strategies of mRNA modification to increase the therapeutic efficacy; we also highlight the recent improvements of mRNA delivery for in vivo applications of gene therapy. Expert opinion: The use of mRNA-based gene transfer could indeed be a promising new strategy for gene therapy. Notable advantages include no risk of integration into the genomic DNA, adjustable gene expression and easier modulation of the immune system. By reducing or utilizing the immunogenic properties, mRNA offers a promising tool for gene/or transcript replacement. Informa Healthcare 2015-09-02 2015-06-30 /pmc/articles/PMC4696419/ /pubmed/26125492 http://dx.doi.org/10.1517/14712598.2015.1057563 Text en © The Author(s). Published by Informa UK, Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Review Youn, Hyewon Chung, June-Key Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy |
title | Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy |
title_full | Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy |
title_fullStr | Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy |
title_full_unstemmed | Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy |
title_short | Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy |
title_sort | modified mrna as an alternative to plasmid dna (pdna) for transcript replacement and vaccination therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696419/ https://www.ncbi.nlm.nih.gov/pubmed/26125492 http://dx.doi.org/10.1517/14712598.2015.1057563 |
work_keys_str_mv | AT younhyewon modifiedmrnaasanalternativetoplasmiddnapdnafortranscriptreplacementandvaccinationtherapy AT chungjunekey modifiedmrnaasanalternativetoplasmiddnapdnafortranscriptreplacementandvaccinationtherapy |